CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.
A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did not meet the primary endpoint.
“But now, this is a comeback kid,” said Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center.
He also highlighted a subgroup analysis of when to best treat patients with relapsed refractory multiple myeloma with
